GLP-1 medications containing semaglutide, including Ozempic and Wegovy, can help with weight management, but people do not respond to them equally. Researchers at the University of Alberta are investigating whether differences in energy metabolism may help explain those varied responses and how weight loss can be maintained.

Research has found that weekly GLP-1 medications, combined with lifestyle interventions for 68 weeks, reduce body weight by an average of 15 per cent. Semaglutide acts on the brain to increase feelings of fullness and decrease appetite. Studies have also associated the medications with improved quality of life, blood markers such as sugar or cholesterol, strength and overall health. Weight loss is only one measure of how well they work.

The University of Alberta team is examining whether responses vary with factors including genetics, metabolism, body composition, lifestyle, microbiota, associated diseases, age and sex. Energy metabolism—the calories consumed and burned—is another possible factor.

As people lose weight, their bodies need less energy. Sometimes they also burn fewer calories than expected, a process called metabolic adaptation, or adaptive thermogenesis. This can make further weight loss more difficult and may contribute to a plateau. Losing fat and fat-free mass also reduces energy use, since both burn calories even at rest.

Researchers are still studying whether weight-loss medications affect these processes differently. A recent review by the team found a few studies on semaglutide and resting energy use, with neutral or inconclusive results. How semaglutide affects energy use remains an open question.

The University of Alberta has a whole-room indirect calorimeter to measure energy use at rest, after eating and during exercise. Researchers are recruiting participants with blood sugar regulation issues, such as insulin resistance or diabetes, who are about to start semaglutide treatment. They will follow participants for six months, measuring changes in weight, body composition and energy use.

The researchers say understanding how semaglutide affects energy use and body composition could help explain why people respond differently and support more personalized approaches to obesity and Type 2 diabetes management. It may also help anticipate potential non-responders—people who do not lose weight—and offer alternative treatments sooner.

Current evidence suggests people taking or considering semaglutide should also make lifestyle changes. Recommendations include increasing protein and choosing fresh foods such as fruits, vegetables, whole grains, lean proteins like fish and poultry, nuts and seeds. The article also recommends small portions at consistent times, avoiding skipped meals, paying attention to hunger and fullness cues, drinking water and doing resistance exercise to support muscle and bone health. These strategies may help limit reductions in energy use during weight loss.

Giovanna Guimaraes Lopes Bergamasco receives funding from the Alberta Diabetes Institute and the Alberta Diabetes Foundation. Andrea M. Haqq is a study principal investigator for clinical trials with Rhythm Pharmaceuticals, Eli Lilly, and Novo Nordisk. Dr. Prado reports speaking engagements and/or consultancy for Abbott Nutrition, Nestle Health Science, Nutricia, and Novo Nordisk. Rachel J. Skow does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Source: The Conversation — Giovanna Guimaraes Lopes Bergamasco, PhD student in Nutrition and Metabolism, University of Alberta, Andrea M. Haqq, Professor, Pediatrics, University of Alberta, Carla Prado, Professor, Department of Agricultural, Food, and Nutritional Science, University of Alberta, Rachel J. Skow, Research Coordinator, Haqq Lab, University of Alberta.